MedPath

G-CSF Administration in IVF in a Preferable Preceptive Endometrium Score

Phase 2
Conditions
Women Infertility
Interventions
Drug: Saline Solution
Procedure: Endometrial scratch
Registration Number
NCT03163862
Lead Sponsor
Istishari Arab Hospital
Brief Summary

This is a controlled preminary trial intended to increase the implantation rate of IVF cycles, by using more than one known procedure, endometrial scratching, evaluating the status of the adhesive factors as αVβ3 integrin, L-selectin ligand MECA-79, E-cadherin and ICAM-1, as a determinant for intervention by G-CSF, according to a score that can be done on a small sample obtained during scratching, then give G-CSF for the scores less than 4 intrauterine and subcutaneously.

Detailed Description

Placebo: CONTROL patients treated with PLACEBO (saline solution) from the day of embryo transfer through the day of beta hCG test Drug\& scratching CONTROL saline infusion every day from the day of embryo transfer through the day of beta HCG test Other Name: SALINE INFUSION Experimental: G-CSF group patients treated with G-CSF if the biopsy adhesive score 1-3 only

1. Endometrial scratching and adhesive factor score, day 21-24 cycle prior to IVF//0rv day 3 of IVF cycle not planned before.

2. Drug \&scratching : G-CSF group

1- 300 µg trans cervical intrauterine of G-CSF was administered at the oocyte retrieval day, 2- subcutaneous 300 micrograms G-CSF on the day of embryo transfer Comparative group patients not treated with G-CSF after scratching if the biopsy adhesive score 4 only

Scratching only :

Patients undergoing scratching on day 21-24 of prior IVF cycle/ and on day 5 of IVF cycle with biopsy score of 4.

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
100
Inclusion Criteria
  • ALL Women aged < 40 years who would be submitted to oocyte retrieval and embryo transfer IN IVF cycle.
Exclusion Criteria
  • • contraindications for G-CSF treatment (sickle cell disease, chronic neutropenia, known past or present malignancy, renal insufficiency, upper respiratory infection, pneumonia, and congenital fructose intolerance)

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboSaline SolutionPatients treated with infusion of PLACEBO (saline solution) from the day of embryo transfer through the day of beta hCG test
G-CSF groupEndometrial scratchPatients treated with G-CSF if the biopsy adhesive score 1-3 only, by Endometrial scratching and adhesive factor scoring on day 21-24 cycle prior to IVF//or day 3 of IVF cycle not planned before. The dose of G-CSF is 300 µg by trans cervical intrauterine route administered at the oocyte retrieval day, Ans subcutaneous 300µg G-CSF on the day of embryo transfer
Comparative groupEndometrial scratchpatients not treated with G-CSF after scratching if the biopsy adhesive score 4 only
G-CSF groupG-CSF administrationPatients treated with G-CSF if the biopsy adhesive score 1-3 only, by Endometrial scratching and adhesive factor scoring on day 21-24 cycle prior to IVF//or day 3 of IVF cycle not planned before. The dose of G-CSF is 300 µg by trans cervical intrauterine route administered at the oocyte retrieval day, Ans subcutaneous 300µg G-CSF on the day of embryo transfer
Primary Outcome Measures
NameTimeMethod
clinical pregnancy per women randomized4 weeks

pregnancy diagnosed by ultrasonographic visualisation of one or more gestational sacs, including ectopic pregnancy

Secondary Outcome Measures
NameTimeMethod
setting a score of precepative endometrium12 months

Evaluation of the endometrial biopsy and setting a receptive score/ adhesive factors of the endometrium

© Copyright 2025. All Rights Reserved by MedPath